Human papillomavirus and head and neck squamous cell carcinoma in a UK population: Is there an association ?
Conclusion: The results we provide suggest that HPV infection is low in HNSCC, in general, and absent in OSCC, specifically, in this UK population during this time period. This implies that HPV infection may not play an important role in HNSCC carcinogenesis compared to other risk factors in UK population. This information can aid in more effective treatment approaches for treating UK cases of HNSCC. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Raghad Al-Dabbagh Nadia Al-Hazmi Turki Y Alhazzazi AW Barrett Paul M Speight Source Type: research
Prevalence and determinants of breast and cervical cancer screening among women aged between 30 and 49 years in India: Secondary data analysis of National Family Health Survey & #8211; 4
Conclusion: A total of 1 out of 10 women in reproductive age group were screened for breast cancer while less than one in three for cervical cancer. Hence, it is important to spread awareness and increase access to screening services to achieve early diagnosis and better treatment outcomes. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Yuvaraj Krishnamoorthy Karthika Ganesh Manikandanesan Sakthivel Source Type: research
Treatment outcome of gestational trophoblastic neoplasia patients in Egypt
Conclusion: Low-risk patients have a survival rate of 100% even if they did not respond to first-line chemotherapy, MTX-FA 8-day regimen seems to be more effective than MTX weekly regimen. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Wael A Edesa Noha N Ayad Ashraf M Mounir Mamdouh H Haggag Source Type: research
Referral mechanism and beneficiary adherence in cervical cancer screening program in Tiruchirappalli district, Tamil Nadu state, India, 2012 & #8211;2015
Conclusion: More than half of the target population was screened in public health facilities. The dropout rate was less than half of those screened at the colposcopy evaluation level. Major pitfalls of the program were human resource issues at referral centers and poor maintenance of meaningful data. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Vidhya Viswanathan Parasuraman Ganeshkumar Jerard M Selvam TS Selvavinayagam Source Type: research
Association of p73 G4C14-A4T14 and p53 codon 72 polymorphism with cervical cancer in Chinese population
Conclusion: These results suggest that there is a statistical difference between p73 and p53 gene polymorphism and the risk of cervical cancer in Chinese women, and there is a potential gene-gene interaction in the incidence of cervical cancer. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Haiyan Guo Zhang Wen Shaodi Yang Hongyan Qi Source Type: research
Different administration methods of endostar combined with second-line chemotherapy in advanced malignancies
Conclusion: In conclusion, no significant difference was observed between the traditional intravenous drip of endostar group and the intravenous drip followed by continuous pumping of endostar group in the patients with advanced malignancies. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Shaoping Chen Jianmei Yang Xin Gao Qiang Liu Xunguo Wang Yanchun Guo Ruibao Liu Fang Wang Source Type: research
FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry & #39;Equivocal & #39; interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience
Conclusions: ALK/ROS1/MET gene alterations were found in 25.18% of NSCLC cases. An ALK IHC “equivocal” interpretation category should be incorporated into practice. Atypical patterns of ROS1 and genomic heterogeneity need to be evaluated further for any clinical relevance. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Angad Singh Rajiv Kumar Omshree Shetty Sangeeta Desai Swapnil Rane Source Type: research
Toolkit for delivering the 3Es and 6As tobacco interventions in dental care
S Sujatha, Asha Iyengar, S Pruthvish, Radhaprashanth , Ravleen NagiIndian Journal of Cancer 2022 59(1):12-17
Tobacco use is one of the major public health problems in India and also the single most important remediable public health problem. Tobacco cessation is the need of the hour. The dentists have a unique opportunity and professional obligation to be a positive influence in reducing the economic and social burden inflicted by tobacco use on dental and general health. However, dentists, in general, have not widely embraced tobacco cessation in practice. In this article, an evidence-based model (an adaptation of the Wo...
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: S Sujatha Asha Iyengar S Pruthvish Radhaprashanth Ravleen Nagi Source Type: research
Therapeutic approaches for relapsed/refractory adult acute lymphoblastic leukemia (ALL), a review on monoclonal antibodies and targeted therapies
Maryam S Hosseini, Leila Jafari, Amir Yami, Ahmad GharehbaghianIndian Journal of Cancer 2022 59(1):4-11
Acute lymphoblastic leukemia (ALL) is the malignant transformation of lymphoid progenitors that affects both children and adults. Although the outcome of pediatric patients has been improved dramatically, there are still many challenges in the treatment of adults. Patients with primary resistant or relapsed disease have the worst outcome and despite the administration of intensified multi-agents chemotherapies, the outcome of this group remains very poor. Accordingly, the development of novel therapeutic options is cons...
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Maryam S Hosseini Leila Jafari Amir Yami Ahmad Gharehbaghian Source Type: research
Self-breast examination for breast cancer screening: The Indian story
Aruni Ghose, Swarnamudra Basak, Tanya AgarwalIndian Journal of Cancer 2022 59(1):1-3 (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - May 19, 2022 Category: Cancer & Oncology Authors: Aruni Ghose Swarnamudra Basak Tanya Agarwal Source Type: research
A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone & #8211;releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix)
Ankur Bahl, Senthil Rajappa, Sudhir Rawal, Ganesh Bakshi, Vedang Murthy, Ketaki PatilIndian Journal of Cancer 2022 59(5):160-174
Luteinizing hormone–releasing hormone agonist (LHRH-A), goserelin, and antagonist, degarelix, are both indicated for the treatment of advanced prostate cancer (PCa); however, large comparative trials evaluating their efficacy and safety are lacking. In this review, we assessed the available evidence for both the drugs. Although degarelix achieves an early rapid decline in testosterone (T) and prostate-specific antigen (PSA) levels, median T and PSA levels, in addition to prostate vo...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Ankur Bahl Senthil Rajappa Sudhir Rawal Ganesh Bakshi Vedang Murthy Ketaki Patil Source Type: research
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
T Raja, Rahul Sud, Sanjai Addla, Kalyan K Sarkar, PS Sridhar, Vikas Talreja, Minish Jain, Ketaki PatilIndian Journal of Cancer 2022 59(5):142-159
Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review, we assessed the efficacy, safety, and convenience of administration of various GnRH-A. All GnRH-A (goserelin, triptorelin, buserelin, histrelin, and leuprorelin) have comparable potential to suppress testosterone (T) levels (≤50 ng/dL in a month and ≤20 ng/dL in 3 months). However, goser...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: T Raja Rahul Sud Sanjai Addla Kalyan K Sarkar PS Sridhar Vikas Talreja Minish Jain Ketaki Patil Source Type: research
Management of human epidermal growth factor receptor 2 & #8211;negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors
Ashok Kumar Vaid, Chetan Deshmukh, Nitesh Rohatgi, Joydeep GhoshIndian Journal of Cancer 2022 59(5):130-141
Human epidermal growth factor receptor 2 (HER2)-negative subset is the most heterogeneous group of metastatic breast cancers (MBCs) as it includes both hormone receptor (HR)-positive and HR-negative breast cancer (or TNBC), which have different therapies and treatment challenges. Though endocrine therapy (ET) remains the treatment backbone in HR-positive HER2-negative cases, about 40% of the patients show intrinsic or acquired resistance to ET due to multiple mechanisms. Combining different therapies such...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Ashok Kumar Vaid Chetan Deshmukh Nitesh Rohatgi Joydeep Ghosh Source Type: research
A review on mechanisms of resistance to PARP inhibitors
Chirag Desai, Anand Pathak, Sewanti Limaye, Vashishth Maniar, Archita JoshiIndian Journal of Cancer 2022 59(5):119-129
Standard therapy for advanced ovarian cancer (OC) consists of radical debulking cytoreductive surgery followed by adjuvant chemotherapy. An important risk factor for OC is genetic predisposition, with BRCA1 or BRCA2 mutations accounting for the majority of hereditary OC. Mutation in BRCA ultimately causes accumulation of genetic alterations because of the failure of cells to arrest and repair DNA damage or to undergo apoptosis, resulting in tumorigenesis. Poly (ADP-ribose) polymerase (PARP) inhibitors hav...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Chirag Desai Anand Pathak Sewanti Limaye Vashishth Maniar Archita Joshi Source Type: research
Significance of emerging clinical oncology endpoints in support of overall survival
Shekar Patil, Vijay Agarwal, HS DrupadIndian Journal of Cancer 2022 59(5):106-118
Despite a better understanding of the pathophysiology and development of newer therapeutic options, cancer remains an area with several unmet needs. Although overall survival (OS) remains a gold standard endpoint for all cancer therapies, it poses challenges such as the requirement of a long-term follow-up, a higher number of patients, and a higher financial burden. Therefore, surrogate endpoints such as progression-free survival, time to progression, duration of response, and objective response rate are being investigated and used in oncolo...
Source: Indian Journal of Cancer - March 24, 2022 Category: Cancer & Oncology Authors: Shekar Patil Vijay Agarwal HS Drupad Source Type: research
